ImmunityBio (IBRX)
(Real Time Quote from BATS)
$2.44 USD
-0.04 (-1.61%)
Updated Oct 14, 2025 11:06 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, ImmunityBio, Inc. has a market cap of $2.44B, which represents its share price of $2.48 multiplied by its outstanding shares number of 984.97M. As a mid-cap company, IBRX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IBRX 2.44 -0.04(-1.61%)
Will IBRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IBRX
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for IBRX
IBRX forms 50 Day Moving Average Resistance on October 13
IBRX forms Directional Movement Crossover Bearish on October 10
Undercovered Dozen: Petrobras, Richtech Robotics, Enbridge And More
Is IBRX likely to continue lower? Fell Below 50 Day Moving Average shows up after sliding 3.56%
Is IBRX gaining bearish strength? 20 Day Moving Average Resistance shows up after climbing 1.2%